Overview

Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant

Status:
Not yet recruiting

Trial end date:
2027-08-15

Target enrollment:

Participant gender:

Summary

A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant. The study includes a run-in period with 20 patients.

Phase:

Phase 2

Details

Lead Sponsor:

University of Utah

Treatments:

Budesonide